Ferrer Unit to Distribute Agendia's MammaPrint, CupPrint Dxs in Spain | GenomeWeb
NEW YORK (GenomeWeb News) — Ferrer in Code will distribute Agendia’s MammaPrint breast cancer recurrence assay and its CupPrint cancer of unknown primary test in Spain, Agendia said today.
 
Agendia CEO Bernhard Sixt said the partners are currently discussing “future steps in order to intensify the co-operation in other parts of the world.”
 
Ferrer in Code is a subsidiary of the pharmaceutical company Ferrer.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.